Impulse Dynamics’ Optimizer III
This article was originally published in The Gray Sheet
Executive Summary
Developer of the cardiac contractility modulation (CCM) therapy for treatment of congestive heart failure completes enrollment in the 430-patient, FIX-HF-5 U.S. randomized clinical trial. The device resembles a pacemaker or implantable defibrillator, but instead of targeting heart rhythm it uses an electrical pulse to modulate the strength of heart muscle contraction (1"The Gray Sheet" Jan. 29, 2007, p. 11)...
You may also be interested in...
Optimizer III Targets Muscle Contractions To Treat Heart Failure; Enters Trial
Impulse Dynamics is 80% enrolled in the U.S. pivotal trial of its Optimizer III cardiac contractility modulation therapy for the treatment of heart failure
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.